EMA Moves To Make Review Of Safety Variations More Efficient
Executive Summary
A new working group at the European Medicines Agency aims to ensure the agency's Pharmacovigilance Risk Assessment Committee (PRAC) is involved in evaluating safety-related variations when needed. These applications were previously assessed by a different committee.